Skip to main content
Fig. 4 | BMC Musculoskeletal Disorders

Fig. 4

From: Evaluation of the expression pattern and diagnostic value of PPARγ in malignant and benign primary bone tumors

Fig. 4

The assessed PPARγ protein expression levels in tumor tissue of malignant bone tumors for the different clinic-pathological variables. The PPARγ protein level was enhanced in chemotherapy-received osteosarcoma and Ewing Sarcoma tumors compared to chemotherapy negative tumors (a). The elevated PPARγ was detected in metastatic tumors compared to non-metastatic tumors in both groups (b). The high grade osteosarcoma tumors expressed higher PPARγ protein level compared to low grade tumors (c) and PPARγ protein level was increased in recurrent tumors compared to non-recurrent groups in both groups (d). The statistical differences between groups are shown as asterisk (*= P < 0.05, **= P < 0.01, ***= P < 0.001)

Back to article page